atos share price

03 Mar 2021. For more information, please visit www.atossatherapeutics.com Forward-Looking Statements Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, whether change in mammographic breast density is an approvable end point for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. “We recently received input from the FDA on this program and based in part on that input, we are now preparing to conduct an additional pre-clinical study, which we expect to start this quarter. Atos SE shares are traded on the Paris Euronext Market under code ISIN FR0000051732. In third party preclinical studies, endocrine-sensitive and letrozole-resistant breast tumors, Z-endoxifen resulted in robust antitumor and antiestrogenic activity compared to tamoxifen and aromatase inhibitor monotherapy. window.al["awardslist_scroll"] = false; Final analysis of the data from the study indicates that there were no serious adverse events, no discontinuations, no bronchospasms, and only one subject of the 32 subjects in the study experienced adverse events that were considered moderate in severity and all other adverse events were considered mild. However, according to McCarthy, further share gains are on the horizon. The company operates under multiple brand names such as Atos, Bull, Atos Healthcare, Unify, Atos Worldgrid, etc. understanding how our webpages are viewed and improving consequently the way our website works, providing you with relevant and personalized marketing content. Based on our forecasts, a long-term increase is expected, the "AEXAY" stock price prognosis for 2026-02-25 is 18.732 USD. Overall, AT-301 was found to be safe and well-tolerated. Market Cap €8.24B. If the drug combination shows promise in this patient, Atossa will consider doing additional clinical studies in patients with ovarian cancer.” Under the FDA expanded access program, the use of Atossa's proprietary oral Endoxifen is restricted solely to this patient. The early-stage data, McCarthy says, suggests AT-301 may prevent viral entry into host cells. DXC's share price was down 9.61 per cent at the time of writing so maybe investors on that side wanted to see a tie-up. window.al["eventsbullet_page"] = 1; The most common treatment-related adverse events observed with AT-301 treatment with either single or multiple doses were nasal discomfort and sneezing. Our website uses cookies to give you the most optimal experience online by: measuring our audience, Low Price. Following that, we expect to apply to the FDA to commence a Phase 2 study here in the United States.” Atossa also plans to develop its nasal spray to potentially help prevent COVID-19 infection -- particularly for people in high-risk environments, such as people living with an infected patient, people living and working in healthcare facilities, emergency responders or teachers. Atos SE (ATO:PAR) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Atossa Therapeutics (NASDAQ:ATOS) Consensus Price Target History About FDA Expanded Access Sometimes called "compassionate use," expanded access is a potential pathway for a patient with serious disease or condition, or an immediately life-threatening condition, to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Share Price & News. Atos Syntel Income Statement. Atos SE quote is equal to 15.020 USD at 2021-03-05. The shares have been listed in Paris since 1995. The next Atos SE dividend is expected to go ex in 2 months and to be paid in 3 months. Date. “Dr. View Financial Services & Insurance solutions, View Healthcare & Life Sciences solutions, View Telecommunications & Media solutions, Atos awarded SEAL Sustainability Award among the top 50 most sustainable companies in the world, Winner of Second Female FinTech competition announced, Atos named a 2020 IDC FinTech Rankings Top 25 Enterprise. Secondary objectives were to assess the incidence and severity of local irritation and bronchospasm following administration of AT-301 via nasal instillation. About Alpelisib Alpelisib was approved in the United States in 2019 for use in combination with the endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. Goff recently contacted Atossa with an interest in gaining access to our Endoxifen under the FDA’s expanded access, or compassionate use, program for one of her patients,” commented Steven Quay, M.D., Ph.D., Atossa’s President and CEO. On average, they anticipate Atossa Therapeutics' stock price to reach $7.50 in the next twelve months. understanding how our webpages are viewed and improving consequently the way our website works, providing you with relevant and personalized marketing content. Atossa’s assessment is that AT-301 nasal spray was safe and well tolerated in this study. window.al["next-event_page"] = 1; window.al["eventsbullet_width"] = 3; window.al = window.al || []; ATOS SEA European public limited-liability company (“Societas Europea”)with a share capital of 109,993,166 eurosRegistered office: River Ouest, 80 Quai Voltaire – 95870 BEZONSPontoise Registry of Commerce and Companies: 323 623 603 Disclosure of trading in own shares Paris, March 4, 2021: Pursuant to applicable law on share buyback, Atos SE declares the following transactions in its own shares … The activation is performed by three human cell surface enzymes, ACE2, furin, and TMPRSS2, and is therefore unaffected by mutations and variants in SARS-CoV-2. Atos SE shares are traded on the Paris Euronext Market under code ISIN FR0000051732. There are currently no FDA-approved therapies to treat COVID-19 at home. We are gratified to be able to help this patient and are anxious to follow her response to this drug combination. Atossa Therapeutics Inc Share price Atossa Therapeutics Inc (ATOS) USD 0.18 Read all the latest ATOS SE Ordinary A US$0.50 share news, regulatory announcements and tips. Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: (866) 893-4927kyle.guse@atossainc.com Investor Relations Contact:Core IROffice:(516) 222-2560ir@atossainc.com Source: Atossa Therapeutics, Inc. Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II), AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma, Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. (See ATOS stock analysis on TipRanks) To find good ideas for coronavirus stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Three human cell surface enzymes - ACE2, furin, and TMPRSS2 - perform the activation and therefore SARS-CoV-2 mutations and variants do not affect it. Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: (866) 893-4927kyle.guse@atossainc.com Investor Relations Contact:Core IROffice:(516) 222-2560ir@atossainc.com Source: Atossa Therapeutics, Inc. A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/a442a892-d657-43b9-b01c-0bbab35a6b49. Additionally, none of the currently available vaccines are 100% effective, they may have more significant side effects in older people, and effectiveness is expected to diminish over time. Volatility Over Time : ATOS's weekly volatility has increased from 21% to 28% over the past year. For more information about this process, please see the FDA website: FDA Expanded Use Website About Atossa's Proprietary Endoxifen Endoxifen is an active metabolite of tamoxifen, which is an FDA-approved drug to treat ovarian and breast cancer. You can accept the cookies by clicking on the “Accept all cookies” button or customize your choices by selecting the cookies you want to activate. With these factors in mind, Maxim analyst Jason McCarthy thinks Atossa Therapeutics (ATOS) could yet have a role to play in fighting the coronavirus. The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is $1.055. About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19. It is very important to do your own analysis before making any investment. Key Data. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19, today announced final results from its Phase 1 double-blinded, randomized, placebo-controlled clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. $ATOS $2.70 is support now!! The Phase 1 study was a double-blinded, randomized, and placebo-controlled safety study of AT-301 nasal spray in 32 healthy adult subjects who were divided into two study groups. McCarthy’s is the only recent analyst review of this company, and it is decidedly positive. The FDA has yet to approve any Covid-19 therapies to be administered at home. Dividend Summary. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 2 million more shares were traded than the day before. If so we should build up support above $3.20. Free forex prices, toplists, indices and lots more. Please find more information on our use of cookies and how to withdraw at any time your consent on our privacy policy. McCarthy’s latest endorsement follows the completion of the Phase 1 study for AT-301, Atossa’s nasal spray drug candidate. Let's see if this goes back to that $3.12 area. window.al["awardslist_page"] = 1; window.al["awardslist_usersel"] = false; window.al["next-event_usersel"] = false; $ATOS Target 4.29 for 27.68% Please only trade my set ups at your own risk. You can also decline all cookies by clicking on the “Decline all cookies” button. The treatment targets recently diagnosed Covid-19 patients whose symptoms aren’t severe enough to require hospitalization. Part B was a multiple dose arm with cohorts receiving either AT-301A or AT-301B for 14 days at two different doses. Rev. window.al["next-event_width"] = 12; #pressreleaseses.pl_grid { margin-bottom: -15px; } #pressreleaseses.pl_grid .pl_slide-wrapper { margin-right: -4px; } #pressreleaseses.pl_grid .pl_grid-item { padding: 0 0 15px 0; } @media (min-width:480px) { #pressreleaseses.pl_grid .pl_grid-item { padding: 0 4px 15px 0; } } @media (min-width:480px) { #pressreleaseses.pl_grid .pl_grid-item.pl_col-sm-12 { padding: 0 0 15px 0; } } #pressreleaseses .blog-summary.blog-date { height: 300px;} #pressreleaseses .pl_grid-item { max-width:390px; }, Olympic and Paralympic Games Worldwide Partner, BTIC – Business Technology Innovation Center, Atos IT Challenge Atos Joseph Fourier Prize, Baixe Registro Universal de Documentos 2019, “Atos Scaler is committed to unleash the value of collaboration, by facilitating open innovation and giving birth to very concrete industrial applications, with accelerated time-to-market.”. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. ... Share price data provided by IEX. window.al = window.al || []; Price trends tend to persist, so it's worth looking at them when it comes to a share like Sprint. AT-301 is intended for this purpose by inhibiting the spike protein activation. AT-301 was considered to be safe and well tolerated in healthy male and female participants in this study at two different dose levels over 14 days. The double-blinded, randomized, placebo-controlled clinical study consisted of 32 healthy adult participants who, over 14 days, received two different dose levels. The available vaccines’ questionable effectiveness against mutant strains and the logistic challenges of worldwide distribution, suggest the battle against the pandemic is not over yet. Combining the leading position of EcoAct in climate strategy consultancy and offset project development with our decarbonization portfolio of solutions and services and our go-to-market will step-change our customers’ journeys to Net Zero”, #pressreleaseses.pl_grid { margin-bottom: -15px; } #pressreleaseses.pl_grid .pl_slide-wrapper { margin-right: -4px; } #pressreleaseses.pl_grid .pl_grid-item { padding: 0 0 15px 0; } @media (min-width:480px) { #pressreleaseses.pl_grid .pl_grid-item { padding: 0 4px 15px 0; } } @media (min-width:480px) { #pressreleaseses.pl_grid .pl_grid-item.pl_col-sm-12 { padding: 0 0 15px 0; } } #pressreleaseses .blog-summary.blog-date { height: 320px;} #pressreleaseses .pl_grid-item { max-width:390px; }, #next-event.pl_grid { margin-bottom: -15px; } #next-event.pl_grid .pl_slide-wrapper { margin-right: -4px; } #next-event.pl_grid .pl_grid-item { padding: 0 0 15px 0; } @media (min-width:480px) { #next-event.pl_grid .pl_grid-item { padding: 0 4px 15px 0; } } @media (min-width:480px) { #next-event.pl_grid .pl_grid-item.pl_col-sm-12 { padding: 0 0 15px 0; } } #next-event .blog-summary.blog-date { height: 280px;}. The organoid testing revealed that the combination of Endoxifen and alpelisib produced an exceptional tumor response. ATOS is good value based on its book value relative to its share price (2.25x), compared to the US market average (64.96x) Day Range 75.32 - 75.98. Latest Share Price and Events. price net variation change % type; 3lub: graniteshares financial plc graniteshares 3x long uber daily etp: usd : 21.65 : 3.23 : 17.55% : etfs : track : 3lts: graniteshares financial plc graniteshares 3x long tesla daily etp: usd : 49.31 : 5.31 : 12.08% : etfs : track : 2tsl: leverage shares public limited co. levshares 2x tesla etp: gbx : 28,514.50 : 3,066.50 : 12.05% : etfs : track : tsl2 Share Price Change. Investors are looking at upside of a strong ~85%, should McCarthy’s thesis play out accordingly over the next 12 months. “The results from this study are very encouraging and we look forward to quickly commencing the next study of AT-301,” commented Steven Quay, M.D., Ph.D., Atossa’s President and CEO. Atos confirmed last month it made an approach to DXC. The content is intended to be used for informational purposes only. The shares have been listed in Paris since 1995. The analyst reiterated a Buy rating on ATOS shares backed by a $5 price target. The shares are not listed on any other stock exchange. Over the past six months, the relative strength of its shares against the market has been 25.7%. Shares Outstanding 109.99M. Atos Syntel revenue breakdown by business segment: 48.9% from Banking and Financial Services, 16.1% from Healthcare and Life Sciences, 13.3% from Insurance, 17.1% from Retail, Logistics and Telecom and 4.6% from Other. Atos (ATO) share price, charts, trades & the UK's most popular discussion forums. “As such, AT-301 administration to patients with mild symptoms as well as prophylactic distribution to high-risk individuals like healthcare workers and teachers could play a role, along with continued vaccine distribution, as a path out of the COVID-19 pandemic.” ATOS has already collected an impressive 190% share haul so far in 2021. The company's shares trade on the Euronext stock exchange. Ticker table to check the latest price updates. window.al["eventsbullet_usersel"] = false; Their average twelve-month price target is $7.50, predicting that the stock has a possible upside of 236.32%. Atos (ATO) 1 Month Share Price History. The primary objectives of the study were to evaluate the safety and tolerability of single and multiple doses of AT-301 administered via nasal instillation to healthy volunteers. Part A consists of two single-dose cohorts receiving either active therapy, AT-301B, or the placebo comparator AT-301A at two different doses. Their forecasts range from $7.00 to $8.00. Subscribe to Premium to view Fair Value for ATOS, SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases today announced the FDA has issued a “Safe to Proceed” letter under their Expanded Access Pathway, permitting the use of Atossa’s oral Endoxifen as a treatment in an ovarian cancer patient. Beta N/A. At the current price of $8.62, shares in Sprint are trading at % against their 200 day moving average. window.al["next-event_scroll"] = false; We are a leading IT services company providing consulting, systems integration and managed operations that improve the effectiveness of our clients’ businesses. The previous Atos SE dividend was 170¢ and it went ex almost 2 years ago and it was paid almost 2 years ago. Alpelisib is marketed by Novartis under the brand name of Piqray. Please find more information on our use of cookies and how to withdraw at any time your consent on our privacy policy. © 2021 Verizon Media. With a 5-year investment, the revenue is expected to be around +24.71%. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy." There is typically 1 dividend per year (excluding specials), and the dividend cover is approximately 6.0. About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19. PIK3 is a family of lipid kinases and one of them, PIK3CA, has mutations or gene amplification detected in 30.5% of all ovarian cancers and 45% of the endometrioid and clear cell subtypes. The intended mechanism of action of AT-301 is to prevent virus entry into human cells by inhibiting the obligatory Spike Protein activation. 2 Wall Street analysts have issued 1 year price targets for Atossa Therapeutics' shares. ATOS SE A European public limited-liability company (“Societas Europea”) with a share capital of 109,993,166 euros Registered office: River Ouest, 80 Quai Voltaire – 95870 BEZONS Access detailed information about the Atos SE (ATOS) Share including Price, Charts, Technical Analysis, Historical data, Atos Reports and more. window.al["eventsbullet_scroll"] = false; 09/03/2021 20:30:35 Cookie Policy +44 (0) 203 8794 460 Free Membership Login The analyst notes that AT-301’s components could be utilized to form in the nasal cavity a protective mucosal barrier, which could get in the way and stop the activation taking place. Therefore closely monitoring the development of the economic health of these two markets is essential. I am not your financial advisor. You can also decline all cookies by clicking on the “Decline all cookies” button. Currency in USD, Trade prices are not sourced from all markets. Skip To Content Skip to content (To watch McCarthy’s track record, click here) Some stocks fly under the radar, and ATOS is one of those. This suggests a possible upside of 202.4% from the stock's current price. High Price. 52 Week Range 43.26 - 82.46. Reuters reported in January, citing sources, that Atos made a formal approach valuing New-York listed DXC at more than $10 billion including debt, in what would have been the deal-hungry IT consulting group's biggest ever acquisition. Stock analysis for Atos SE (ATO:EN Paris) including stock price, stock chart, company news, key statistics, fundamentals and company profile. New deadlier and/or more infective variants of COVID-19 are being reported in the U.S. and in many other countries and it is not clear that current vaccines will be completely effective against these and future variants. Our website uses cookies to give you the most optimal experience online by: measuring our audience, Stock analysis for Worldline SA/France (WLN:EN Paris) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Approval from the Institutional Review Board (IRB) must be obtained prior to providing oral Endoxifen to this patient. The high price target for ATOS is $8.00 and the low price target for ATOS is $7.00. per Employee €106.98K. To learn the latest Atos share price, follow Capital.com. Atossa Therapeutics Stock Forecast, ATOS stock price prediction. The shares are not listed on any other stock exchange. Futures holding green for now. Atossa has been developing its proprietary oral Endoxifen for breast cancer and other breast conditions and has successfully completed five clinical studies with this drug, including an expanded access study of a female breast cancer patient who has been taking oral Endoxifen for over two years, with no recurrence to date. Welcome to Investor Relations at Atos. The purchase of DXC, which is this week due to reveal its third-quarter financial results for fiscal 2021, would have been a mouthful for Atos. The study was being conducted in Australia. Latest Share Price and Events Stable Share Price : ATOS is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 28% a week. “The patient has recurrent ovarian cancer and recently underwent functional molecular genomic testing, using 3D tumor organoid cultures grown in the laboratory from the patient’s tumor. French IT firm Atos, U.S. rival DXC end deal talks. The Atos share price is particularly sensitive to British and North American economic conditions. Atossa believes that AT-301 nasal spray will play an important role alongside the traditional vaccines now being deployed, particularly as it becomes clear that it will take months or years for vaccines to be administered around the world. About Ovarian Cancer In 2021 ovarian cancer will be diagnosed in about 21,400 women in the United States and about 13,770 women will die from the disease. Download the Healthcare Look Out 2020+ Paper, Central Government Local Governments and Cities Homeland Security Public Safety Space Defense Education, Olympic & Paralympic Games Sports & Major events, Download “Towards the new normal: finding a balance in the hybrid society” paper, Download the Telecom Look Out 2020+ Paper, “The acquisition of EcoAct, an Atos company, is a major step towards our decarbonization ambition. It has a market capitalisation of €7,402m, with approximately 110m shares in issue. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. How has Atos's share price performed over time and what events caused price changes? “It is relatively unlikely that subsequent mutations and novel strains of COVID-19 will modify this activation process, which is essential for SARS-CoV-2 propagation,” the 5-star analyst noted. Your current $100 investment may … Stable Share Price: ATO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week. You have full control over what you want to activate. All rights reserved. The price has been going up and down for this period, and there has been a -2.75% loss for the last 2 weeks. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. window.al = window.al || []; window.al["awardslist_width"] = 12; #awardsglobal.pl_grid { margin-bottom: -15px; } #awardsglobal.pl_grid .pl_slide-wrapper { margin-right: -4px; } #awardsglobal.pl_grid .pl_grid-item { padding: 0 0 15px 0; } @media (min-width:480px) { #awardsglobal.pl_grid .pl_grid-item { padding: 0 4px 15px 0; } } @media (min-width:480px) { #awardsglobal.pl_grid .pl_grid-item.pl_col-sm-12 { padding: 0 0 15px 0; } } #awardsglobal .blog-summary.blog-date { height: 280px;}. Share Price % Change. Public Float 94.87M. The patient is being treated at the University of Washington Medical Center by Dr. Barbara Goff, Surgeon-in-Chief. Based partially on FDA input, the company is planning an additional pre-clinical study which it hopes to kick off in the current quarter, following which Atossa will apply to move forward with a Phase 2 trial. For more information, please visit www.atossatherapeutics.com Forward-Looking Statements Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Share Price. Shares Traded. Shares in Atos Se (EPA:ATO) are currently trading at 68.02, but a key question for … Open €75.60.

Steam Card Colombia, Wedding Ceremony Set Up, What Is A 1099 Miscellaneous Form, Ikea Discount Code Australia, Valentine Cards Handmade, Berkeley Bike Map, My Palmerston Vouchers, Perforated Paper For Tickets, Kaandossiwin How We Come To Know Summary,